98%
921
2 minutes
20
Purpose: Autosomal recessive CARD9 deficiency predisposes patients to invasive fungal disease. Candida and Trichophyton species are major causes of fungal disease in these patients. Other CARD9-deficient patients display invasive diseases caused by other fungi, such as Exophiala spp. The clinical penetrance of CARD9 deficiency regarding fungal disease is surprisingly not complete until adulthood, though the age remains unclear. Moreover, the immunological features of genetically confirmed yet asymptomatic individuals with CARD9 deficiency have not been reported.
Methods: Identification of CARD9 mutations by gene panel sequencing and characterization of the cellular phenotype by quantitative PCR, immunoblot, luciferase reporter, and cytometric bead array assays were performed.
Results: Gene panel sequencing identified compound heterozygous CARD9 variants, c.1118G>C (p.R373P) and c.586A>G (p.K196E), in a 4-year-old patient with multiple cerebral lesions and systemic lymphadenopathy due to Exophiala dermatitidis. The p.R373P is a known disease-causing variant, whereas the p.K196E is a private variant. Although the patient's siblings, a 10-year-old brother and an 8-year-old sister, were also compound heterozygous, they have been asymptomatic to date. Normal CARD9 mRNA and protein expression were found in the patient's CD14 monocytes. However, these cells exhibited markedly impaired pro-inflammatory cytokine production in response to fungal stimulation. Monocytes from both asymptomatic siblings displayed the same cellular phenotype.
Conclusions: CARD9 deficiency should be considered in previously healthy patients with invasive Exophiala dermatitidis disease. Asymptomatic relatives of all ages should be tested for CARD9 deficiency. Detecting cellular defects in asymptomatic individuals is useful for diagnosing CARD9 deficiency.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10875-021-00988-7 | DOI Listing |
Photodermatol Photoimmunol Photomed
September 2025
Dermatology Department, Hospital Regional Universitario de Málaga, Malaga, Spain.
Front Cell Infect Microbiol
July 2025
Center for Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Caspase recruitment domain containing protein 9 (CARD9) deficiency is an autosomal-recessive primary immunodeficiency disorder, undermines the body's capacity to combat fungal infections. In recent years, the number of reported cases of fungal infections associated with CARD9 deficiency has been increasing. This study undertook a systematic review of case reports, incorporating 89 patients with CARD9 deficiency complicated by fungal infections.
View Article and Find Full Text PDFInt J Mol Sci
July 2025
Department of Mycology and Genetics, Faculty of Biological Sciences, University of Wrocław, Przybyszewskiego 63-77, 51-148 Wrocław, Poland.
is an emerging black yeast recognized in both superficial and life-threatening infections, including those in immunocompetent hosts. This narrative review focuses on recent developments (mostly between 2019 and 2025) in two major areas. First, we examined the clinical and epidemiological background of , with particular focus on its involvement in cystic fibrosis and CARD9 deficiency, as well as central nervous system, ocular, and systemic infections.
View Article and Find Full Text PDFJCI Insight
July 2025
Department of Microbiology & Immunology, McGill University, Montréal, Québec, Canada.
Human Caspase Recruitment Domain Containing Protein 9 (CARD9) deficiency predisposes to invasive fungal disease, particularly by Candida spp. CARD9 deficiency causes chronic central nervous system (CNS) candidiasis. Currently, no animal model recapitulates the chronicity of disease, precluding a better understanding of immunopathogenesis.
View Article and Find Full Text PDFJ Eur Acad Dermatol Venereol
May 2025
Department of Dermatology and Venerology, Peking University First Hospital, The Research Center for Medical Mycology, Peking University, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing, China.